why choose us

First received: August 5, 2022

Clinical Trial: Apixaban vs Dual Antiplatet Therapy Study After Left Atrial Appendage Occlosure (ADALA)

Study Status: Completed

Recruit Status: Completed

Condition: Left Atrial Appendage Occlusion

Study Type: Interventional


Official Title: Antithrombotic Therapy After Left Atrial Appendage Occlusion: Double Antiplatelet Therapy vs Apixaban

Brief Summary: Objective: To demonstrate superiority of a strategy of anticoagulation with apixaban 5mg/2.5mg bid as compared with the current standard of care (dual antiplatelet therapy) after occlusion of the left atrial appendage (LAAC) in patients with atrial fibrillation (AF).Rationale: Data on antithrombotic therapy after LAAC are scarce and no randomized evaluation has been performed to demonstrate what is the best antithrombotic strategy. LAAO in patients without contraindication to chronic anticoagulants (PROTECT-AF…

Read more